Enhanced production of ergothioneine in Aspergillus oryzae
Applied Microbiology and Biotechnology · 2025
DOI: 10.1007/s00253-025-13505-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, 2025. Verfasst von Lihong Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science, Jiangxi Science & Technology Normal University, Nanchang, 330013, Jiangxi, China. Hauptthemen laut MEDLINE: Aspergillus oryzae, Ergothioneine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Ergothioneine (EGT) is a sulfur-containing amino acid derivative with unique antioxidant properties, and was first identified in Claviceps purpurea in 1909 (Han et al. 2021 ). Most plants and animals, including humans, cannot synthesize EGT, being mainly obtained from the diet (Pochini et al. 2019 ; Tschirka et al. 2018 ) and accumulates in metabolically active tissues, such as the liver, kidneys, and intestines (Tang et al. 2018 ). Through specific transporters, EGT can be delivered to sites of oxidative damage, reducing cellular oxidative stress (Deiana et al. 2004 ; Halliwell et al. 2018 ). In recent years, EGT has been classified as a “longevity vitamin” (Wijesekara and Xu 2024 ), highlighting its significance in human physiology. Previous studies have suggested its potential as a therapeutic agent for neurodegenerative disorders, demonstrating its ability to enhance hippocampal neurogenesis and mitigate age-related brain damage (Katsube et al. 2024 ; Nakamichi et al. 2016 ). Additionally, EGT exhibits protective effects against chronic diseases, such as cardiovascular disease and diabetes (Wu et al. 2021 ). In 2017, EGT has been recognized as a “Generally Recognized As Safe (GRAS)” substance (EFSA Panel on Dietetic Products, Nutrition and Allergies et al. 2017 ) and has become a multifunctional ingredient in nutraceuticals and cosmeceuticals. Its anti-aging properties, particularly in skin barrier repair and collagen synthesis, have also gained attention in recent years (Hseu et al. 2020 ; Liu et al. 2023 ; Tsay et al. 2021 ). However, despite its broad applications, microbial production of EGT remains inefficient (Takusagawa et al. 2019 ; Zhu et al. 2022 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Science, Jiangxi Science & Technology Normal University, Nanchang, 330013, Jiangxi, China.
- Jiangxi Key Laboratory of Natural Microbial Medicine Research, Jiangxi Science & Technology Normal University, Nanchang, 330013, Jiangxi, China.
- College of Life Science, Jiangxi Science & Technology Normal University, Nanchang, 330013, Jiangxi, China. gaoruineau@163.com.
- Jiangxi Key Laboratory of Natural Microbial Medicine Research, Jiangxi Science & Technology Normal University, Nanchang, 330013, Jiangxi, China. gaoruineau@163.com.
- College of Life Science, Jiangxi Science & Technology Normal University, Nanchang, 330013, Jiangxi, China. huzhihong426@163.com.
- Jiangxi Key Laboratory of Natural Microbial Medicine Research, Jiangxi Science & Technology Normal University, Nanchang, 330013, Jiangxi, China. huzhihong426@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, L., Tian, X., Xue, P., Deng, Y., Gao, R., & Hu, Z. (2025). Enhanced production of ergothioneine in Aspergillus oryzae. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-025-13505-2
Vancouver
Wang L, Tian X, Xue P, Deng Y, Gao R, Hu Z. Enhanced production of ergothioneine in Aspergillus oryzae. Applied Microbiology and Biotechnology. 2025. doi:10.1007/s00253-025-13505-2
BibTeX
@article{Wang2025,
author = {Wang, Lihong and Tian, Xueqin and Xue, Pinghong and Deng, Yunhong and Gao, Rui and Hu, Zhihong},
title = {Enhanced production of ergothioneine in Aspergillus oryzae},
journal = {Applied Microbiology and Biotechnology},
year = {2025},
doi = {10.1007/s00253-025-13505-2}
}
EUVIMED